{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Control+Subjects&page=13",
    "query": {
      "condition": "Control Subjects",
      "page": 13
    },
    "page_size": 10
  },
  "pagination": {
    "page": 13,
    "page_size": 10,
    "total_count": 5448,
    "total_pages": 545,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Control+Subjects&page=14&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Control+Subjects&page=12&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-19T21:27:25.026Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02109406",
      "title": "Efficacy and Safety Study of Two Dose Levels of AZD2115 in Subjects With Moderate to Severe COPD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease (COPD)"
      ],
      "interventions": [
        {
          "name": "AZD2115 Dose 1",
          "type": "DRUG"
        },
        {
          "name": "AZD 2115, Dose 2",
          "type": "DRUG"
        },
        {
          "name": "Placebo MDI",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pearl Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 31,
      "start_date": "2014-05",
      "completion_date": "2014-09",
      "has_results": false,
      "last_update_posted_date": "2020-09-02",
      "last_synced_at": "2026-10-19T21:27:25.026Z",
      "location_count": 3,
      "location_summary": "Clearwater, Florida • Charleston, South Carolina • Spartanburg, South Carolina",
      "locations": [
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Charleston",
          "state": "South Carolina"
        },
        {
          "city": "Spartanburg",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02109406"
    },
    {
      "nct_id": "NCT00354809",
      "title": "Evaluation of A Morning Dosing Of A New Medicine And Its Effects On Sleep At Bedtime In Subjects With Primary Insomnia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sleep Initiation and Maintenance Disorders",
        "Insomnia"
      ],
      "interventions": [
        {
          "name": "GW679769",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 68,
      "start_date": "2006-05",
      "completion_date": "2007-07",
      "has_results": false,
      "last_update_posted_date": "2015-04-16",
      "last_synced_at": "2026-10-19T21:27:25.026Z",
      "location_count": 13,
      "location_summary": "Glendale, Arizona • Glendale, California • Hallandale, Florida + 10 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Hallandale",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Fayetteville",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00354809"
    },
    {
      "nct_id": "NCT04683848",
      "title": "Study to Assess the Efficacy and Safety of MT-3921 in Subjects With Acute Traumatic Cervical Spinal Cord Injury",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Spinal Cord Injury"
      ],
      "interventions": [
        {
          "name": "MT-3921",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Tanabe Pharma America, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 72,
      "start_date": "2021-08-27",
      "completion_date": "2025-04-09",
      "has_results": false,
      "last_update_posted_date": "2025-12-16",
      "last_synced_at": "2026-10-19T21:27:25.026Z",
      "location_count": 15,
      "location_summary": "Orange, California • Tallahassee, Florida • Augusta, Georgia + 12 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Tallahassee",
          "state": "Florida"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04683848"
    },
    {
      "nct_id": "NCT03096392",
      "title": "Comparison of Hepatic Directed Vesicle (HDV)-Insulin Lispro Versus Insulin Lispro to Further Improve Glycemic Control",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 1"
      ],
      "interventions": [
        {
          "name": "HDV insulin lispro 100 UNT/ML",
          "type": "DRUG"
        },
        {
          "name": "Insulin Lispro 100 UNT/ML",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Diasome Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 46,
      "start_date": "2017-04-18",
      "completion_date": "2018-03-18",
      "has_results": false,
      "last_update_posted_date": "2018-07-31",
      "last_synced_at": "2026-10-19T21:27:25.026Z",
      "location_count": 5,
      "location_summary": "Aurora, Colorado • Miami, Florida • Morehead City, North Carolina + 1 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Morehead City",
          "state": "North Carolina"
        },
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03096392"
    },
    {
      "nct_id": "NCT03525444",
      "title": "A Phase 3 Study of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cystic Fibrosis"
      ],
      "interventions": [
        {
          "name": "VX-445/TEZ/IVA",
          "type": "DRUG"
        },
        {
          "name": "IVA",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vertex Pharmaceuticals Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 405,
      "start_date": "2018-06-15",
      "completion_date": "2019-04-24",
      "has_results": true,
      "last_update_posted_date": "2020-05-19",
      "last_synced_at": "2026-10-19T21:27:25.026Z",
      "location_count": 53,
      "location_summary": "Tucson, Arizona • Little Rock, Arkansas • Long Beach, California + 48 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Madera",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03525444"
    },
    {
      "nct_id": "NCT06456593",
      "title": "Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Moderately to Severely Active Crohn Disease"
      ],
      "interventions": [
        {
          "name": "Obefazimod",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Abivax S.A.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 212,
      "start_date": "2024-10-30",
      "completion_date": "2028-04",
      "has_results": false,
      "last_update_posted_date": "2026-04-27",
      "last_synced_at": "2026-10-19T21:27:25.026Z",
      "location_count": 43,
      "location_summary": "Fairhope, Alabama • Scottsdale, Arizona • Sun City, Arizona + 40 more",
      "locations": [
        {
          "city": "Fairhope",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Murrieta",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06456593"
    },
    {
      "nct_id": "NCT02834793",
      "title": "Study of Perampanel as Adjunctive Treatment for Inadequately Controlled Seizures Associated With Lennox-Gastaut Syndrome",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Lennox-Gastaut Syndrome (LGS)"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Perampanel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eisai Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 101,
      "start_date": "2016-12-13",
      "completion_date": "2021-07-19",
      "has_results": true,
      "last_update_posted_date": "2022-03-09",
      "last_synced_at": "2026-10-19T21:27:25.026Z",
      "location_count": 31,
      "location_summary": "Little Rock, Arkansas • Palo Alto, California • Gulf Breeze, Florida + 25 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Gulf Breeze",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Loxahatchee Groves",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02834793"
    },
    {
      "nct_id": "NCT01527916",
      "title": "Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "placebo",
          "type": "DRUG"
        },
        {
          "name": "donepezil",
          "type": "DRUG"
        },
        {
          "name": "ABT-126",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie (prior sponsor, Abbott)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "55 Years to 90 Years"
      },
      "enrollment_count": 438,
      "start_date": "2012-02",
      "completion_date": "2013-11",
      "has_results": false,
      "last_update_posted_date": "2014-11-19",
      "last_synced_at": "2026-10-19T21:27:25.026Z",
      "location_count": 8,
      "location_summary": "Delray Beach, Florida • Tampa, Florida • West Palm Beach, Florida + 5 more",
      "locations": [
        {
          "city": "Delray Beach",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "West Palm Beach",
          "state": "Florida"
        },
        {
          "city": "Elk Grove Village",
          "state": "Illinois"
        },
        {
          "city": "Staten Island",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01527916"
    },
    {
      "nct_id": "NCT04176133",
      "title": "Entolimod on Immunosenescence in Healthy Geriatric Subjects Receiving Influenza Vaccination",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Entolimod",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Influenza vaccine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Robert J. Pignolo",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 61,
      "start_date": "2019-10-30",
      "completion_date": "2022-03-30",
      "has_results": true,
      "last_update_posted_date": "2023-06-22",
      "last_synced_at": "2026-10-19T21:27:25.026Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04176133"
    },
    {
      "nct_id": "NCT04041648",
      "title": "Single Ascending Dose Study for Evaluation of Safety, Tolerability and Pharmacokinetics of L606",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pulmonary Arterial Hypertension"
      ],
      "interventions": [
        {
          "name": "L606 (Liposomal Treprostinil) Inhalation Solution 51ug",
          "type": "DRUG"
        },
        {
          "name": "L606 Inhalation System",
          "type": "DEVICE"
        },
        {
          "name": "Placebo Solution",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE",
        "OTHER"
      ],
      "sponsor": "Pharmosa Biopharm Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 52,
      "start_date": "2018-11-09",
      "completion_date": "2020-05-12",
      "has_results": false,
      "last_update_posted_date": "2025-08-05",
      "last_synced_at": "2026-10-19T21:27:25.026Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04041648"
    }
  ]
}